Aldeyra Therapeut (Nasdaq: ALDX) announced that it has opened enrollment for its Phase II clinical trial of NS2 for patients ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE